Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma

Recently, neurabin-I and SAMD14 have been described as the autoantigenic target of approximately 66% of B-cell receptors (BCRs) of primary central nervous system lymphomas (PCNSL). Neurabin-I and SAMD14 share a highly homologous SAM domain that becomes immunogenic after atypical hyper-N-glycosylatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bewarder, Moritz, Kiefer, Maximilian, Moelle, Clara, Goerens, Lisa, Stilgenbauer, Stephan, Christofyllakis, Konstantinos, Kaddu-Mulindwa, Dominic, Fadle, Natalie, Regitz, Evi, Neumann, Frank, Hoth, Markus, Preuss, Klaus-Dieter, Pfreundschuh, Michael, Thurner, Lorenz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689012/
https://www.ncbi.nlm.nih.gov/pubmed/33282736
http://dx.doi.org/10.3389/fonc.2020.580364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689012/
https://www.ncbi.nlm.nih.gov/pubmed/33282736
http://dx.doi.org/10.3389/fonc.2020.580364

Ejemplares similares